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Neuro 2A cells infected with a retroviral ' :ctor carryin|t human prosomatostatin eDNA expressed and proces~d con'eetly ihc precursor into soma. 
tostatins-14 and .28 [(1989} EMBO J, 1~. 2911,,~2916], in order to stud~, the mechanisms by which the active hormone sequences arise, site directed 
mutagenesis was performed on either the dibasic (AqlLysl or monobasic [Argl cleavage sites involved in the produclion of somalostatin=. 14 and 
.28, respectively, Radioimmtmochemie:d amtly~is ~f the somatostafin.rdated product~ indicated tha! repl:lcement ofeither Arg"-'.Ly~* ~by AIn ==- 
Ash" b or of Ar~" ~j' by Asn '~ resulted In the exclusive production ofeither somatostatin.28 or-14. respectively, Moreover only prosomatostatin[ b, 
76] was detected and no somatostatin-28[l-12] could b¢ measured incell extracts, Selective suppression feither somatostatm. 14 or somatostatln.2l~l 
release by mutation did not affect he I¢v¢1 of production of the other hormone but resulted in a correlative increase of unprocessed prosomatostatia, 
Iris concluded that in this cell type (i) somatostatin.14 is exclusively generated by dibasic le~val~e at the Arg"a-Lys "~ site of the intact precursor 
with concomitant productr ~n of prosomatostatin[ I~76], and (ill no direct interactions between the monobasie and dibasic processing domains occur. 
Endoprote:tse; Somatostatin radioimmunoassay; Site.directed mutagenesis: Basic residue 
1. INTRODUCTION 
In mammals ,  p rosomatostat in  appears  to be the pro-  
duct  o f  express ion o f  a single gone. Therefore ,  genera-  
t ion o f  somatostat in -14  (S-14) and  somatostat in -28 
(S-28) pept ide sequences involves d i f ferent ia l  process-  
ing o f  a unique precursor  by pept ide  bond hydrolys is  at  
e i ther  a d ibasic  (RK) or a monobas ic  (R) c leavage site 
(F ig ,  1), This system provides indeed a very useful  
mode l  to unders tand  how di f ferent ia l  maturat ion  o f  a 
s ingle prohormone molecule can generate hormona l  
d ivers i ty  by  means  o f  mult ip le c leavage loci recogn i t ion  
by the enzyme machinery  (for a review see [1]). Gone 
t rans fer  techniques of fer  unique possibi l i t ies to s tudy 
the process ing o f  neuropept ide  precursors  in cu l tured 
cell l ines. Using this technology,  we have shown pre-  
v ious ly  [2,3] that  infect ion of  Neuro2A cells with a 
ret rov i rus  carry ing the human prosomatostat in  eDNA 
resul ted in the process ing of  the precursor  into approx-  
imate ly  equal  amounts  of  somatost in-28 (S-28) and  
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somatostat in -14  (S-14), In the present study,  site- 
d i rected mutagenesis  was per fo rmed to analyse separa-  
tely the two possib le prosomatostat in  process ing path-  
ways.  The  data indicate that,  in this cell type,  either 
S-14 or  S-28 appear  to be produced independent ly  and 
that  fur ther  processing of  P ro -S [ l -72]  into P ro -  
S[1-64] ,  or  of  S-28 into S-28[1-12] and S-1414-6] does 
not  occur,  
2. MATERIALS  AND METHODS 
2,1. DNA nzantpulations, construction of eAT~ression vectors and cell 
cll#ure 
DNA modifications and subcloning, site-directed mutagenesis and 
construction of the pN2Som retroviral expression vectors was per- 
formed exactly as described previously [2,3] The retroviral sequences 
of pN2 are derived from the Moloncy routine leukemia virus [7], it 
contains both LTRs and the sequences required for production of in- 
fectious viruses, In such constructs, the expression of prosomato- 
statin is driven by the SV40 early promoter while the bacterial gone 
conferring the resistance to the neomycin analog G418 is under the 
control of tt~e retrovirus 5'LTR, The transcription termination/ 
polyA addition signals are provided by the virus 3' LTR. The presence 
of tile mutations in the expression vectors was confirmed by sequenc- 
ing the mutated regions by the chain-termination method for double- 
stranded templates using T7 DNA polymerase [8]. Table 1 lists the 
mutants constructed for the present studies. 
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T~bl¢~ 1
,%ltll,,'tltd ro¢~¢1t¢~ 01'htim¢tll pro~ctllta|p~lt~lllt; Ih¢' follsswhlM fltll|Ci|~vd ~Llen¢~'~ wilr¢ ¢~pr¢l~,fd 
~flcr Iran,Lf~nion I Neuro]A ~:~ll,i, 
P ROSO,MATO~TATI t4 IA r j  ~ o ~ A~n" ~l 
~IUTANI" h tArO *''~) 
,~ ~l~.$¢t',Al~l.~t~ .Ser.A ~n,Pro,AI:~.Mez .Ala, Pro-Artt,,Ghl-Arl~. Ly~.~M~.fDly,Cy~.Ly~.A.sn 
Art..Ser,Ala.Asn.Ser.A~t~.Pro.Al=t.MeX.Ala.Pro.Ar~.Glu. Asn~A~n- AIa.GIy-Cy~- ky~.A'~n 
MUTANT I lh (Gly ~'~) 
Arg.Ser,AIn.A~n.Set.A st~.GI.y.Ala.Met .Aht.Pro.A rg.Glu.Art~.Ly,~.Ala.Gly.Cys- l~).s;.A~n 
MLITANT IV: (Ala ~'] 
A~t=~Se~'Aht-Asn~Ser-As~.A~a.Ala.Met.Ala-Pro.A~.Gh~-Arg.t.y~Ala-G~y-Cy~Lys.Asn 
MUTANT V: [AhC '~) 
A~d~S~r~A~a~A~n~S~r~Asn~r~A~M¢t~A~8~Arg~G~u~Ar~Lys~Aht~G~y~Cys~Ly~Asn 
MUTANT Vh (Ala =v, Ala "~) 
Arg.Scr-Ala-ASl~-Ser.Asn.Al~.Ala .Met-Ala;t3Ja-Arg.Glu.Arg-Lys-Ala.Gly-Cys-Lys.Asn 
MUTANT VII: (Ala "v, Asn "~) 
~Asr~-S~r-A~a-Asn.Ser-Asn..~.A~a.M~t-A~a-Pro-Arg.Gh~-Arg-Lys-A~a.G~y-Cys-Lys-Asn 
MUTANT Viii: (Ala "'J, Asn'=.Asn =t) 
Arg.Ser-Ala-Asn.Scr-Asn.AJ~.Ala.Met-Ala-Pro-Arg.Glu-~st3: .A~,I-Ala.Gly-Cys-Lys-Asn 
The substitued residues are underlined 
Mutants II1, IV, V and VI were taken from [2,3], 
M~.y 19~)I 
2,2, Analysis of  somatostatita-relateg p ptides 
Subconfluent nfected Nearo2A ceils were harvested in Tris- 
buffered saline (TBS) containing 4 mM EGTA (3 ml per Petri dish), 
An equal volume of 2 × extraction solution (1 x extraction solution: 
1 M HCI, 5o/o formic acid, 1 0/o trifluoro-acetie acid (TFA), 0.2°70 
2-mercaptoethanol and I% NaCI) [9] is added and the cell suspension 
sonicated twice for 30 s, The cell debris were pelleted and the superna- 
tant passed through an ODS-silica cartridge (Sep-pak C18, Waters) 
equilibrated with 0,1 070 TFA, The adsorbed peptides were eluted with 
4007o acetonitrile in 0.1% TFA, Control experiments using S.14 and 
S-28[1-121 as standards allowed to determine a recovery ield for this 
filtration ~>80%, TFA and acetonitrile were eliminated by lyophi- 
lization an0 the dry peptides resuspended in 507o acetic acid, The 
amounts of precursor, S-28 and S.14 in the cell extracts were deter- 
mined by running the samples on a C18 reverse-phase HPLC column 
(nucleosil 5~; 250 × 4 mm) eluted isocraticaliy with 23070 acetonitrile 
and 0,05 % TFA at a flow rate of 1 ml. rain-~ during 40 min, followed 
by a gradient of acetonitrile (23070 to 100°70) in25 rain, l-ml fractions 
were collected and then assayed for the presence of immunoreactive 
species using a specific radioimmunoassay as described in [2]. Iden- 
tification of Pro-S[l-76] was performed after the HPLC separation 
on the same samples using a specific RIA for S-28[1-12] [4,6], Iden- 
tification of Pro-S[I-92], S-28 and S.14 was performed similarly on 
the recovered HPLC fractions using a specific RIA for S.14 [2,6], 
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3. RESULTS AND DISCUSSION 
In mammals ,  processing of p rosomatostat in  results 
in the product ion  of two biological ly active peptides, 
somatostat in -28 (S-28) and  somatostat in -14 (S-14). The 
biogenesis of" S-14 can be accompl ished via two distinct 
processing pathways of the common precursor  (path- 
ways I and  II, Fig. I). In the first scheme, S-14 is pro- 
duced directly by proteolysis of  the precursor  at a pair 
of  basic amino  acids (Arg-~-Lys- t ) .  In the second 
scheme, S-28 is first generated by proteolysis of  the pre- 
cursor at a single arginyl  residue (Arg-15), fo l lowed by 
proteolysis of  the Arg-2-Lys - t  site result ing in the 
release of  S-14 and S-28[I-12].  
In order to separately analyse these two pathways, 
mutat ions  affect ing selectively either the Arg -~ or the 
Arg -2 .Lys - t  sites (mutants  I and  II,  respectively; Table 
I )  were thus  created in the human prosomatostat in  
eDNA and  the extracts of infected Neuro2A cells 
ana lyzed  with sensitive S-14 and S-28[1-12] radioim- 
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munoassays, The results presented in Table II indicate 
unequivocally that isosteric replacement of the basic 
amino acids by Asn selectively abolished either S-28 or 
S-14 production, In cells expressing mutant 1, neither 
S-28 nor S-28[1-121 could be detected whereas in cells 
expressing mutant II, abolishment of S-14 production 
was accompanied by the disappearance of detectable 
amounts of Pro-S[ 1-76], These results are in agreeme~At 
with in vitro [10,11] and in vivo [121 studies indicating 
that the modification or lhe substitution of basic 
residues abolished recognition of the site by the process- 
ing enzymes. 
Moreover, selective suppression of  cleavage at either 
the monobasic or the dibasic site did not result in a 
significant increase in cleavage at the other site but 
rather led to a correlative increase in the ratio of un- 
processed prosomatostatin (Pro-S[l-92]) detected in 
cell extracts (Table II). These observations could be ex- 
plained by postulating the presence of two types of 
maturation enzymes, each one involved in the recogni- 
tion of a specific site {Arg-Z-Lys -t~ or Arg "~ site). It is 
also possible that these enzyn~es might be located in dif- 
fercnt compartments of the secretory pathway [6]. 
Although very unlikely, our results do not rule out the 
possibility that the mutations affect the folding of the 
precursor, retarding its exit from the rough endo- 
plasmic reticulurn and thus accounting for the increased 
intracellular content in the precursor. Results by others 
indeed suggest hat the information ecessary for the 
correct addressing of prosoraatostatin is probably con- 
tained in the NHz-terminal [1-62] portion [13], a do- 
main which was not affected directly by the here 
reported mutations. 
Since the yield of S-28 was similar in the extracts of 
cells infected with the unmutated precursor and with 
mutant II, one can conclude that S-28, produced by 
monobasic cleavage at the Arg -~5 site, does not 
undergo further processing at its Arg-2-Lys - t site. This 
conclusion was supported by the observation that only 
Pro-S[1-76] and no S-28[1-12] could be detected in the 
extracts of cells infected with the unmutated cDNA. 
These results indicate that (i) in Neuro2A cells, S-I4 is 
produced exchtsively by the processing of Pro-S[1-921 
at its dibasic Arg'a-Lys "t site, and (ii) production of 
hormonat sequences occurs independently. 
In previous work [21. it was demonstrated that Pro -'~ 
and Pro "'~ residues are essential in prosomatostatin pro.
cessing. In particular, replacement of Pro -9 (mutant 
IV) and Pro -s (mutant V) by Ala abolished selectively 
S-28 and S-14 release from the precursor, an cffect ten. 
tatively attributed to local disruption of an ordered 
Table I1 
Effects of various mutations on prosomatostatin processing in 
transfeeted Neuro2A cells 
Mutants S.28 S.14 Pro-S[I-921 Pro.S[1-76] 
Unmutated 120 100 50 39 
(44) (37) (19) 
I 0 161 153 66 
(52) (48) 
II 90 0 103 0 
(46) (54) 
I I 1 265 496 34 62 
(4) (65) (4) 
I V 0 68 59 11 
(53) (47) 
v 60 0 130 0 
(31) (69) 
Vi 45 0 118 0 
(27) (73) 
VII 0 77 115 39 
(40) (60) 
Vlll 0 0 165 0 
(1oo) 
The amounts of S-28, S-14, Pro-S[l-92] and Pro-S[l-76] were 
evaluated by RIA using antibodies against somatostatin-14 or
somatostatin-28[1-12]. Results are expressed it, pg of 'S-14' or 
'S-2811-12]' for the latter, Numbers in parentheses represent the frac. 
tion of respective forms calculated as percentage oI total somatostatin 
immunoreactivity, For direct comparison, tile amount of 
somatostatin related peptides detected per 10 ° cells is also presented, 
In order to allow comparisons with other mutants results for mutants 
III, IV, V and VI were taken from [2,3]. 
365 
Voh~me 282, number 2 FEBS LETTERS 
20 
15 
¢4 
BII 
5 
I | t l t l l l  |1  H i l l | t i t  | t  I | l l | , | l  I | l~t | l  l i t  | l t l l | t l t l l t l i l l l t lU l l l l  
" #,=ll'~, 121 Pte , i t t  ,16| 
[ 
F I l l  I I  ~11111 I I I I I I  I I  I I  I I  I I  I T l~ l l l l l  I I I  I I I I l l l  I I I  ~111111111111!11  I 
11 21 31 41 51 61 
FRACTION NUMBER 
200 I l l l l l l  In I l t i * l i l l l l * la t l l ' l l l l  I I  la  I l l l l  I1 |  I I I  I I I l l l l l l l l l | l l l l l  
5,~0 
8,14 
150 ~ ~  
== ~0o 
5O 
0 I ~  I I I ~] | r |  | I |T IT | ' t ]~r~IT I I~] ] ] ' I  I1  ¥11 I '1Y |T I  l |~ l  I ' l  I | I l ' l  
11 21 31 4~ 51 61 
FRACTION NUMBER 
Fig, 2, HPLC analysis of prosomatostatin a d of its processing 
fragments. Top. lmmunochemical evaluation of Pro.S [I-76] and 
S.28 [I-12] after reverse.phase HPLC separation as described in sec. 
tion 2. RIA were run using anti S-28 [1-12] antibodies [3] Bottom, hn- 
munochemical detection of Pro-S [1-92], S.28 and S-14 after HPLC 
separation using a specific RIA with anti S. 14 antibodies [2] (see sec- 
tion 2), 
secondary structure [2,3]. Moreover it could be shown 
that the importance of the proline residue at position@ 
was due to its contribution to a secondary structure 
since replacement of Pro -9 by GIy "9 a strong B-turn 
former (mutant III) did not affect cleavage at the 
Arg -!s site [3], Indeed the results obtained with the 
double mutant (Ala -9, Ale-S; i.e. mutant VI) suggested 
that these effects were not exclusively related to local 
secondary structure ffects but were possibly attributed 
to more complex interactions occurring at the tertiary 
level I2,3], In order to analyse possible effects of 
replacement of Pro "9 by Ala -9 on each individual pro- 
cessing site, mutants VII and VI I I  were constructed, 
Results obtained with the double mutant Ala -9, Asn -ts 
(mutant VII) demonstrate that Ala -9 replacement for 
Pro -9, which was shown previously to interfere with 
processing at the Are- ts  site, did not affect cleavage at 
the dibasic site; Indeed the proport ion of S-14 re- 
covered f rom cell extract was very similar to that found 
in the ea,~e or the wild ty~c. Similarly lhe observation 
that triple mutation Ale" , A, sn°=-A~n= I (mutam VII I)  
resulted in abol ishment of  S-28 prodtlctlOll, reinforces 
the previou~ conclusions that the two proee~in~t motifs 
involved in S.14 and S-28 production by selective pro. 
teolysis proce~sin~l appear to be fttqetion.ally inde- 
pendent, 
Prosomatostat in  clearly constitutes a remarkable 
model since this particular prohormone molecule 
possesses intrinsic properties which allow various cell 
types to process this precursor according to selective 
differential metabolic pathways. When compared with 
lower organisms (like tcleostean fishes [14] where two 
distinct and scaregated precursor molecules provide the 
supply for different hormonal  at:tivities, the mam- 
malian system appears as a more sophisticated one 
allowing for hormonal  diversity by modulation of pro- 
teolytic cleavages, The question tl~en arises as to the 
source o f  these properties. The present data obtained 
on a clonaI cell lilxc suggest, indeed, that differential 
processing o f  a single prohormone is achieved by two 
mechanisms. The first ono deals with the structural 
properties of  the prohormone molecule and the second 
one possibly involves subcellular segregation of the pro- 
cessing events and of  the corresponding enzyme 
machinery. It can be envisioned that in situ co-localiza- 
tion of  the processing events occurring in the Golgi ap- 
paratus [6,15,16] and of  the enzyme(s) involved in such 
reactions will provide further insight in these important 
mechanisms 
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